CompletedNot Applicable

EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction

France142 participantsStarted 2011-07-11

Plain-language summary

The purpose of this study is to assess the potential prognostic value of seric concentrations of EG-VEGF for Pre-eclampsia and/or intrauterine growth restriction and will allow checking whether plasma levels of EG-VEGF at 14-18 weeks of gestation could be proposed as prognostic marker for preeclampsia.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women older than 17 years old * All pregnant patients enrolled before 14 SG and with singleton, irrespectively of their parity * Pregnant woman living in the Grenoble area * Women accepting, the participation to the study. Exclusion Criteria: * Inability to understand the project * Persons deprived of their liberty by judicial or administrative decisions * Person under legal protection

What they're measuring

Measure of the circulating levels of EG-VEGF in the sera of pregnant woman between 14 and 18 WG

Timeframe: Between 14 and 18 weeks of gestation

Trial details

NCT IDNCT01490489

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2015-03

View on ClinicalTrials.gov More Pre-eclampsia trials